The clinical performance of PAX1, SOX1, and ZNF582 as biomarkers of cervical neoplasm has been validated in multi-center clinical trials; therefore, analysis of changes in the methylation status of these genes could be applied for self-collected vaginal samples. This evidence concerns the gene SOX1 and uterine cervix neoplasm.